This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
These observations are procedural in nature and none of them are related to data integrity
Subscribe To Our Newsletter & Stay Updated
